他莫昔芬诱发非酒精性脂肪性肝病的研究进展  

Research progress on nonalcoholic fatty liver disease induced by tamoxifen

作　　者：赵斐[1,2] 展玉涛[1] 

机构地区：[1]首都医科大学附属北京同仁医院消化科,北京100730 [2]北京大学首钢医院超声医学科,北京100144

出　　处：《现代药物与临床》2015年第8期1041-1045,共5页Drugs & Clinic

基　　金：北京市教育委员会科技发展计划面上项目(KM201510025017)

摘　　要：他莫昔芬是一种广泛应用于治疗激素敏感型乳腺癌的抗雌激素类药物。临床研究和动物实验已经证实他莫昔芬可以诱发非酒精性脂肪性肝病(NALFD)。目前认为他莫昔芬诱发NALFD的机制主要包括脂肪酸的合成、脂肪酸的β氧化、三酰甘油转运异常以及雌激素拮抗作用。对他莫昔芬诱发NAFLD及其发病机制的研究现状进行了综述。Tamoxifen is an anti-estrogen drug widely used for the treatment of hormone-sensitive breast cancer. Clinical research and animal studies have confirmed that tamoxifen can induce nonalcoholic fatty liver disease（NALFD）. So far, the pathogenesis of NALFD induced by tamoxifen include synthesis of aliphatic acid, β-oxidation of aliphatic acid, abnormal export of triacylglycerol, and inhibition of estrogens. The NAFLD induced by tamoxifen and its pathogenesis are reviewed in this paper.

关 键 词：他莫昔芬 非酒精性脂肪性肝病 发病机制 

分 类 号：R977.1[医药卫生—药品] R979.1[医药卫生—药学]